Joined Today: 0

AMRN Amarin Plc, Stock Message Board

All Messages

AMRN Message Board Home | Join The AMRN Group |

#13: AMEN Stock News : Amarin Announces Results from Exploratory Phase 2a Study of EN101 in Myasthenia Gravis
TheMachine	June 10, 2009 08:03:22 AM
Amends Ester Neurosciences Acquisition Agreement Amarin Corporation plc (NASDAQ:AMRN) today announced encouraging top line results from an exploratory Phase 2a multi-centre,... view message ignore post recommend post

#12: Amarin Regains Compliance With Nasdaq Listing Requirements
TheMachine	February 16, 2008 02:44:38 AM
LONDON, February 11 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRND) today announced that it has received notification from The Nasdaq Stock... view message ignore post recommend post

#11: Amarin Appoints Dr. William Mason as Lead Independent Director
TheMachine	February 16, 2008 02:44:15 AM
LONDON, February 4 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRND) today announced that its Board of Directors has established the position of... view message ignore post recommend post

#10: Dutton Associates Announces Investment Opinion: Amarin Rating Raised To Speculative Buy By Dutton Associates
TheMachine	February 16, 2008 02:43:55 AM
Dutton Associates continues coverage of Amarin Corporation plc (Nasdaq: AMRN), raising its rating to Speculative Buy and a price target at $7.00. The 15-page report by... view message ignore post recommend post

#9: Amarin Signs Agreement to Acquire Ester Neurosciences
Stock News Bot	December 12, 2007 05:56:52 AM
Adds Promising Phase II Neurology Candidate $8.1 Million Financing in Connection With Acquisition Reverse Stock Split Planned for January 2008 LONDON, December 5 /PRNewswire-FirstCall/... view message ignore post recommend post

#8: Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program
FastFun	December 1, 2007 06:13:05 PM
Initiates Phase I Clinical Trial to Evaluate Ultra-Pure Ethyl EPA-Niacin for Treatment of Niacin- Induced Flushing LONDON, November 29 /PRNewswire-FirstCall/ -- Amarin Corporation plc... view message ignore post recommend post

#7: Amarin Announces Completion of Comprehensive Data Analysis From
FastFun	December 1, 2007 06:10:49 PM
LONDON, November 19 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRN) ('Amarin' or 'Company') today announced that management has met with the U.S. Food and Drug... view message ignore post recommend post

#6: Amarin Announces Initiation of Cardiovascular Development Strategy
FastFun	October 17, 2007 10:31:13 PM
Capitalizing on Known Therapeutic Benefits of Unsaturated Fatty Acids in Cardiovascular Disease LONDON, October 10 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRN) today... view message ignore post recommend post

#5: Amarin to Present at 4th Annual Bio Investor Forum
FastFun	October 17, 2007 10:30:37 PM
LONDON, October 9 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Rick Stewart, Chief Executive Officer, will present at the 4th Annual Bio Investor... view message ignore post recommend post

#4: Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
FastFun	October 17, 2007 10:30:03 PM
Pre-Clinical Study Results for Memory and Cognition Validate Clinical Development Program LONDON, September 24 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRN) ('Amarin'... view message ignore post recommend post

#3: AMRN News Dutton Associates Announces Investment Opinion: Amarin Rating Maintained At Strong Speculative Buy By Dutton Associates
Stock News Bot	February 28, 2007 09:00:00 AM
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Dutton Associates continues coverage of Amarin Corporation plc (Nasdaq:AMRN), maintaining its rating at Strong Speculative Buy and its price... view message ignore post recommend post

#2: AMRN News Dutton Associates Announces Investment Opinion: Amarin Rating Raised To Strong Speculative Buy By Dutton Associates
Stock News Bot	July 25, 2006 09:00:00 AM
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--July 25, 2006--Dutton Associates continues coverage of Amarin Corporation plc (Nasdaq:AMRN), increasing its rating to Strong Speculative Buy and... view message ignore post recommend post

#1: AMRN News MultiCell Technologies In-Licenses Phase IIb/III Drug for the Treatment of Fatigue in Multiple Sclerosis from Amarin Corporation
Stock News Bot	January 3, 2006 03:00:00 AM
LINCOLN, R.I. & LONDON--(BUSINESS WIRE)--Jan. 3, 2006--MultiCell Technologies, Inc. (OTCBB: MCET) and Amarin Corporation plc (NasdaqSC: AMRN) announced today that MultiCell has exclusively licensed... view message ignore post recommend post

Group Home | Login if you want to post a message